We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRRX
101
DELISTED
DURECT Corp
DRRX
$2.05M 0.12%
152,852
-27,148
-15% -$347K
RDHL
102
Redhill Biopharma
RDHL
$4.44M
$2.01M 0.12%
192
+128
+200% +$1.53M
ABUS icon
103
Arbutus Biopharma
ABUS
$871M
$1.94M 0.11%
792,617
-85,914
-10% -$250K
INSM icon
104
CALL
Insmed
INSM
$22.6B
$1.93M 0.11%
1,459
– –
SGMO
105
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.88M 0.11%
6,177
+566
+10% +$2.06K
EDIT icon
106
Editas Medicine
EDIT
$402M
$1.87M 0.11%
115,000
-20,000
-15% -$304K
CLVS
107
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$1.87M 0.11%
420
-1,671
-80% -$58.8K
PVLA
108
Palvella Therapeutics
PVLA
$2.05B
$1.81M 0.11%
16,200
-3,091
-16% -$383K
OPK icon
109
Opko Health
OPK
$1.23B
$1.78M 0.1%
+190,955
New +$1.98M
WGBS
110
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.77M 0.1%
358,535
+42,812
+14% +$188K
CYTR
111
DELISTED
CytRx Corp
CYTR
$1.75M 0.1%
782,967
-454,497
-37% -$1.34M
VXZ
112
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$1.74M 0.1%
50,000
-15,000
-23% -$538K
NBSE
113
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.74M 0.1%
+2,891
New +$3.05M
NTLA icon
114
Intellia Therapeutics
NTLA
$1.52B
$1.7M 0.1%
130,000
+25,159
+24% +$378K
PRTK
115
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.69M 0.1%
110,000
-65,000
-37% -$844K
SRPT icon
116
CALL
Sarepta Therapeutics
SRPT
$1.63B
$1.68M 0.1%
611
-2,915
-83% -$117K
LUMO
117
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.62M 0.09%
176
-145
-45% -$16.3K
ESRX
118
DELISTED
Express Scripts Holding Company
ESRX
$1.62M 0.09%
+23,494
New +$1.68M
ACAD icon
119
PUT
Acadia Pharmaceuticals
ACAD
$4.45B
$1.58M 0.09%
+548
New +$14.5K
OCGN icon
120
Ocugen
OCGN
$420M
$1.58M 0.09%
15,748
+14,951
+1,876% +$2.07M
IOVA icon
121
Iovance Biotherapeutics
IOVA
$2.1B
$1.57M 0.09%
226,081
-20,261
-8% -$139K
FWP
122
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.56M 0.09%
14,896
+746
+5% +$98.3K
MDCO
123
CALL
DELISTED
Medicines Co
MDCO
$1.55M 0.09%
457
-693
-60% -$24.6K
ROKA
124
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$1.55M 0.09%
+365,220
New +$1.84M
VCYT icon
125
Veracyte
VCYT
$4.44B
$1.5M 0.09%
+193,999
New +$1.45M
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.